View in EDS

Discovery of Tivumecirnon (FLX475), a Potent and Selective CCR4 Antagonist That Inhibits the Migration of Immunosuppressive Regulatory T Cells into the Tumor Microenvironment to Restore Antitumor Immunity.

Saved in:
Bibliographic Details
Title: Discovery of Tivumecirnon (FLX475), a Potent and Selective CCR4 Antagonist That Inhibits the Migration of Immunosuppressive Regulatory T Cells into the Tumor Microenvironment to Restore Antitumor Immunity.
Authors: Robles O; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Brockstedt DG; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Aponte-Guzman J; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Bradford D; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Chian D; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Colas C; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Grandcolas M; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Hu DX; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Jackson J; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Jacobson S; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Karbarz E; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Kassner PD; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Katibah GE; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Ketcham JM; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Marshall L; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., McKinnell J; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Meleza C; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Milestone H; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Okano A; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Qiu J; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Reilly MK; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Riegler E; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Shunatona HP; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Talay O; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Younai A; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Ziari N; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Zibinsky M; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States., Wustrow DJ; RAPT Therapeutics, 561 Eccles Ave, South San Francisco, California 94080, United States.
Source: Journal of medicinal chemistry [J Med Chem] 2026 Jul 13. Date of Electronic Publication: 2026 Jul 13.
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1520-4804
DOI:10.1021/acs.jmedchem.6c00683